New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
08:12 EDTESPREsperion Therapeutics initiates Phase 2 study of ETC-1002
Esperion Therapeutics announced dosing of the first patient in its Phase 2 clinical study of ETC-1002 in patients with hypercholesterolemia and hypertension, ETC-1002-014. The company expects to announce top-line results from the study in the second quarter of 2015. The randomized, double-blind, parallel group, multicenter ETC-1002-014 study is evaluating parallel doses of ETC-1002 in approximately 144 patients. The primary objective of the study is to assess the LDL-cholesterol lowering efficacy of ETC-1002 monotherapy versus placebo in patients with both hypercholesterolemia and hypertension who are treated for six weeks. Secondary objectives include assessing the effect of ETC-1002 on blood pressure, other lipid and cardiometabolic biomarkers and characterizing the tolerability and safety of ETC-1002.
News For ESPR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:16 EDTESPREsperion shares should rally by early 2015, says Citigroup
Citigroup says it believes Esperion shares as "substantially undervalued" and that overhangs on the stock should be lifted by early 2015, leading to a "significant correction." Citi expects benign animal cancer results to ease regulatory hurdles and investor concerns. It keeps a Buy rating on the stock with a $63 price target.
November 21, 2014
07:51 EDTESPRBofA/Merrill biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 19, 2014
07:52 EDTESPRInforma Business Information to hold a conference
Subscribe for More Information
November 17, 2014
07:09 EDTESPRAmerican Heart Association to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use